Search clinical trials for: GSK1349572 (dolutegravir)

Total 222 results

Fundacion IDEAA
ViiV Healthcare

Completed

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test (D2ARLING)

Hiv | HIV-1-infection

Argentina
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Infection, Human Immunodeficiency Virus

United States
MRC/UVRI and LSHTM Uganda Research Unit
Janssen Pharmaceuticals

Recruiting

Improving HIV-1 Control in Africa With Long Acting Antiretrovirals (IMPALA)

HIV-1-infection

South Africa, Kenya, Uganda
Andrew Carr
ViiV Healthcare Australia Pty. Ltd

Completed

The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis (dPEP)

Human Immunodeficiency Virus

Australia
Charlotte-Paige Rolle, MD
ViiV Healthcare

Completed

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF (DYAD)

HIV I Infection

United States
Fundacion SEIMC-GESIDA
ViiV Healthcare

Active, not recruiting

DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: (PASO-DOBLE)

HIV-1-infection

Spain
NEAT ID Foundation
ViiV Healthcare

Completed

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N (WISARD)

HIV-1-infection

Spain, Belgium, France, Germany, Italy, United Kingdom
Philip Grant

Withdrawn

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) (ReNew)

HIV/AIDS | Osteopenia | HIV-1-infection

United States
Indiana University

Completed

Pharmacokinetics of JULUCA in Hemodialysis

HIV/AIDS | ESRD

United States
ViiV Healthcare

Completed

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Argentina, Spain, Germany, Belgium, Australia, Canada, United Kingdom, Italy, Romania, Taiwan, Russian Federation, Mexico, France, Switzerland, Peru, Poland, Portugal
Fondation Ophtalmologique Adolphe de Rothschild

Terminated

Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting (NEPAL)

HIV

France
ANRS, Emerging Infectious Diseases

Recruiting

Evaluation of Third-line cART Regimen in Cambodia (3DICAM)

HIV/AIDS

Cambodia
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

HIV Infections | Infection, Human Immunodeficiency Virus

Taiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
University of North Carolina, Chapel Hill
ViiV Healthcare

Completed

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection (PHI-05)

HIV | Acute HIV Infection

United States
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density

HIV-1 Infection

Spain
Azienda Ospedaliera Universitaria Senese
Catholic University of the Sacred Heart; Ospedale Policlinico San Martino; Azienda... and other collaborators

Unknown

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (DOBINeuro)

HIV-1-infection

Italy
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (FLAMINGO)

Infection, Human Immunodeficiency Virus

Spain, France, Germany, United States, Italy, Romania, Russian Federation, Switzerland, Puerto Rico
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Rapid HIV Treatment Initiation, Access and Engagement in Care

Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
Centre for the AIDS Programme of Research in South...
Johns Hopkins University; National Institute of Allergy and Infectious Diseases... and other collaborators

Active, not recruiting

INSTI's For The Management of HIV-associated TB (INSIGHT)

HIV/AIDS | Tuberculosis, Pulmonary

South Africa
Cristina Mussini

Unknown

Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF)

HIV Infections
ANRS, Emerging Infectious Diseases
Mylan Laboratories

Active, not recruiting

ANRS 12372 MODERATO Study (MODERATO)

HIV-1-infection

Côte D'Ivoire, Burkina Faso, Cameroon
Desmond Tutu TB Centre
University of Stellenbosch; UNITAID; Chiang Mai University

Recruiting

Pharmacokinetics and Safety of DolutegravIr in Neonate (PETITE-DTG)

Hiv

South Africa
Swiss Tropical & Public Health Institute
University of Basel; Ministry of Health, Lesotho; District Health Management... and other collaborators

Completed

Dolutegravir in Real Life in Lesotho (DO-REAL)

HIV-1-infection

Lesotho
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
ViiV Healthcare

Completed

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

HIV-1 Infection

Spain
Thomas Benfield

Recruiting

Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil (AVERTAS-2)

HIV Infections | Obesity | Renal Insufficiency | Osteoporosis | Hiv | Weight Gain | HIV Lipodystrophy

Denmark
Helen Reynolds
Desmond Tutu HIV Centre; Infectious Disease Institute, Kampala, Uganda

Active, not recruiting

Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin (DoRIS)

Tuberculosis | Hiv

Uganda, South Africa
ViiV Healthcare
GlaxoSmithKline

Completed

A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)

Infection, Human Immunodeficiency Virus

Germany
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal Disease

HIV

Spain
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Expanded Access Study (DEAP)

HIV Infections | Infection, Human Immunodeficiency Virus

France, Germany, United States, Canada, Belgium, Austria, Brazil, Italy, Poland
Radboud University Medical Center
University Medical Center Groningen; Erasmus Medical Center; Leiden University...

Withdrawn

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls. (POLO)

Hepatic Impairment | HIV-1-infection
Institut de Médecine et d'Epidémiologie Appliquée...

Completed

Kinetics of HIV-RNA Decay in Seminal Plasma of Men Treated by Dolutegravir at the Time of Primary HIV Infection (DOLUPRIM)

HIV Infection Primary
Calmy Alexandra

Completed

A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients (MONODO)

Human Immunodeficiency Virus | Treatment Efficacy | Monotherapy | Dolutegravir

Switzerland
Africa Health Research Institute

Recruiting

Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT (LAPIS)

HIV Infections

South Africa
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus
University of Nairobi
ViiV Healthcare

Completed

Second-line Switch to Dolutegravir Study (2SD)

HIV-1-infection

Kenya
St Stephens Aids Trust

Completed

Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)

HIV

Germany, Spain, France, United Kingdom, Belgium, Italy
Cliniques universitaires Saint-Luc- Université...

Completed

Gut Microbiota, PGx and INSTIs Response

HIV Infections

Belgium
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare; Mylan Inc.

Recruiting

Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

HIV-associated Tuberculosis

South Africa, Thailand
Castagna Antonella
Bristol-Myers Squibb; ViiV Healthcare

Completed

A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia (Dolatav)

HIV-1 Infection

Italy
Fundacion Clinic per a la Recerca Biomédica

Unknown

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

HIV-1-infection | Solid Organ Transplant

Spain
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence (ENLIGHTEN)

HIV/AIDS

United States
Chelsea and Westminster NHS Foundation Trust

Completed

The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers (DTG Clamp)

HIV-1-infection on Healthy Volunteers

United Kingdom
Fundação Bahiana de Infectologia

Completed

Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients (IDEA)

Severely Immunocompromised HIV Patients

Brazil
University of Liverpool
Liverpool School of Tropical Medicine; Desmond Tutu Health Foundation

Recruiting

Doravirine Dose Optimisation in Pregnancy (DoraDO)

HIV

South Africa
ViiV Healthcare
GlaxoSmithKline

Terminated

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

HIV Infections

United States, Taiwan, Peru, Canada, Thailand, Australia, Puerto Rico, Russian Federation, Argentina, Mexico, Colombia, South Africa, Chile
South East Asia Research Collaboration with Hawaii
Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences; Thai Red Cross AIDS Research... and other collaborators

Recruiting

Antiretroviral Therapy for Acute and Chronic HIV Infection (AAHIV)

Acute HIV Infection | Chronic HIV Infection

Thailand
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

Infection, Human Immunodeficiency Virus

United States

Search clinical trials for: GSK1349572 (dolutegravir)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations